Trial Profile
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide; Nivolumab; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Jan 2024 This study has been completed in Poland, according to European Clinical Trials Database record.
- 05 Jan 2024 Planned End Date changed from 20 Dec 2023 to 29 Mar 2024.
- 05 Jan 2024 Planned primary completion date changed from 20 Dec 2023 to 29 Mar 2024.